Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | F2 | P00734 | 3/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10637725 | 0.85 | ALDH1A1 (0.60) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL443434 | 0.83 | ALDH1A1 (0.53) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL21753530 | 0.82 | ALDH1A1 (0.49) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL28003017 | 0.82 | ALDH1A1 (0.52) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL26088501 | 0.82 | ALDH1A1 (0.52) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL10412878 | 0.82 | ALDH1A1 (0.52) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3365461 | 0.82 | ALDH1A1 (0.52) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| Urea SCHEMBL28325104 | 0.82 | ALDH1A1 (0.52) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5685915 | 0.81 | ALDH1A1 (0.56) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8827511 | 0.81 | TSHR (0.52) | ALDH1A1F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954826-A | Compound, preparation method and application thereof, lithium ion battery electrolyte additive and electrolyte | 华鼎国联动力电池有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-114478303-A | Method for synthesizing carbidopa | 浙江野风药业股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20210347776-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | CADILA HEALTHCARE LIMITED (IN) | 2021-11-11 | — | — | US | claimed |
| JP-6025147-A | — | — | None | — | — | JP | disclosed |
| EP-4565282-A1 | IMMUNOSTIMULATORY ANTI-PD-L1-DRUG CONJUGATES | Seagen Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119954826-A | Compound, preparation method and application thereof, lithium ion battery electrolyte additive and electrolyte | 华鼎国联动力电池有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250090875-A9 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-03-20 | — | — | US | disclosed |
| US-20240165251-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | SEAGEN INC (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117769544-A | Polysubstituted thiazole derivative and application thereof in disease treatment | 上海汇伦医药股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2024030577-A1 | IMMUNOSTIMULATORY ANTI-PD-L1-DRUG CONJUGATES | SEAGEN INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-4288109-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | Seagen Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-102827082-A | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD | 2012-12-19 | — | — | CN | disclosed |
| EP-1264840-B1 | Long lasting fusion peptide inhibitors of viral infection | CONJUCHEM BIOTECHNOLOGIES INC (CA) | 2009-09-23 | — | — | EP | disclosed |
| JP-H0625147-A | BIS @(3754/24) P-TOSUENESULFONYLAMINOCARBONYLAMINO) DIPHENYL COMPOUND | NEW OJI PAPER CO LTD | 1994-02-01 | — | — | JP | disclosed |
| EP-0260823-B1 | IMPROVEMENTS IN OR RELATING TO PRINTING PLATE PRECURSORS | E.I. du Pont de Nemours and Company (US) | 1993-06-09 | — | — | EP | disclosed |
| US-4999271-A | Photopolymerizable urethane acrylate or methacrylate, lithography | VICKERS PLC (GB) | 1991-03-12 | — | — | US | disclosed |
| EP-0260823-A2 | Improvements in or relating to printing plate precursors | E.I. du Pont de Nemours and Company (US) | 1988-03-23 | — | — | EP | disclosed |
| EP-0098729-B1 | OXIME DERIVATIVES AND PROCESSES OF FORMING POLYMERIC OXIMES | POLAROID CORPORATION (US) | 1986-10-08 | — | — | EP | disclosed |
| US-4510294-A | REMOVAL OF BLOCKING GROUPS AFTER FORMING THE ADDITION POLYMER | POLAROID CORPORATION (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0098729-A1 | Oxime derivatives and processes of forming polymeric oximes | POLAROID CORPORATION (US) | 1984-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090875-A9 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | CD47, FCGR2A, ICOS | ALDH1A1 784/4885F2 4821/4885PRSS1 4124/4885 |
| US-20240165251-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | CD47, FCGR2A, ICOS | ALDH1A1 784/4885F2 4821/4885PRSS1 4124/4885 |
| US-20210347776-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | ADCYAP1R1, GANC, DRD4 | ALDH1A1 1208/4885F2 917/4885PRSS1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.